Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Nov;25(11):2065-2066.
doi: 10.1002/ejhf.3053. Epub 2023 Oct 18.

Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long-term survival

Alwin Tubben  1   2 , Hans L A Nienhuis  2   3 , Peter van der Meer  1   2
Affiliations
Free article
Editorial

Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long-term survival

Alwin Tubben et al. Eur J Heart Fail. 2023 Nov.
Free article
No abstract available

PubMed Disclaimer

Comment on

References

    1. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al.; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007-1016. https://doi.org/10.1056/NEJMoa1805689
    1. Elliott P, Gundapaneni B, Sultan MB, Ines M, Garcia-Pavia P. Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms. Eur J Heart Fail 2023;25:2060-2064. https://doi.org/10.1002/ejhf.2974
    1. Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail 2022;15:e008193. https://doi.org/10.1161/CIRCHEARTFAILURE.120.008193
    1. Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, et al. Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy. JACC Heart Fail 2021;9:115-123. https://doi.org/10.1016/j.jchf.2020.09.011
    1. Li H, Rozenbaum M, Casey M, Sultan MB. Estimating the effect of tafamidis on cardiovascular-related hospitalization in nyha class iii patients with transthyretin amyloid cardiomyopathy in the presence of death. Cardiology 2022;147:398-405. https://doi.org/10.1159/000525883

MeSH terms

Supplementary concepts